Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986249 alone and with nivolumab in advanced solid tumors
NCT03369223Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of BMS-986249 in solid tumor (advanced stage), melanoma, hepatocellular carcinoma (HCC), castration-resistant prostate cancer (CRPC), triple-negative breast cancer (TNBC), sponsored by Bristol Myers Squibb. Started Dec 2017; status: completed.
02
Drugs
BMS-986249
03
Conditions
solid tumor (advanced stage)melanomahepatocellular carcinoma (HCC)castration-resistant prostate cancer (CRPC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03369223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369223.